Position in ABVX
as of Mar 31, 2026
· filed May 6, 2026
Position Value
$5,567,500
New position
Shares Held
50,000
first reported quarter
Ownership
0.063%
of shares outstanding
% of Portfolio
0.37%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026SEVEN GRAND MANAGERS, LLC holds $103,028,834 across 33 Biotechnology names. ABVX ranks #6 (5.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NKTR |
Nektar Therapeutics
|
125,000 | $8,993,750 | |
| 2 | DRUG |
Bright Minds Biosciences Inc.
|
120,000 | $8,756,400 | |
| 3 | APGE |
Apogee Therapeutics, Inc.
|
100,000 | $8,417,000 | |
| 4 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
100,000 | $8,392,000 | |
| 5 | PVLA |
Palvella Therapeutics, Inc.
|
60,000 | $7,479,000 | |
| 6 | ABVX |
Abivax S.A.
This page
|
50,000 | $5,567,500 | |
| 7 | SYRE |
Spyre Therapeutics, Inc.
|
100,000 | $5,044,000 | |
| 8 | MANE |
Veradermics, Inc
|
74,750 | $4,720,462 |
All Filings in ABVX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,567,500 | 50,000 | Shares | Sole | 2026-05-06 | |
| No filing history on record for this holder in this stock. | ||||||